The effects of oral ENA713 and CHF2819 (0.5, 1.5 and 4.5 mg/kg), two novel acetylcholinesterase inhibitors, on extracellular concentrations of amino acids in rat hippocampus, were evaluated using in vivo microdialysis. ENA713, at 4.5 mg/kg, but not CHF2819, significantly decreased glutamate, taurine, arginine and citrulline levels, without affecting aspartate concentrations. These results suggest that the modulation of amino acidergic transmission could represent an additional mechanism of action in Alzheimer's disease for some acetylcholinesterase inhibitors. (C) 2001 Elsevier Science B.V. All rights reserved.
Effects of ENA713 and CHF2819, two anti-Alzheimer’s disease drugs, on rat amino acid levels / Trabace, L; Cassano, T; Cagiano, R; Tattoli, M; Pietra, C; Steardo, Luca; KENDRICK K., M; Cuomo, Vincenzo. - In: BRAIN RESEARCH. - ISSN 0006-8993. - STAMPA. - 910(1-2):(2001), pp. 182-186. [10.1016/S0006-8993(01)02653-1]
Effects of ENA713 and CHF2819, two anti-Alzheimer’s disease drugs, on rat amino acid levels
STEARDO, LUCA;CUOMO, VINCENZO
2001
Abstract
The effects of oral ENA713 and CHF2819 (0.5, 1.5 and 4.5 mg/kg), two novel acetylcholinesterase inhibitors, on extracellular concentrations of amino acids in rat hippocampus, were evaluated using in vivo microdialysis. ENA713, at 4.5 mg/kg, but not CHF2819, significantly decreased glutamate, taurine, arginine and citrulline levels, without affecting aspartate concentrations. These results suggest that the modulation of amino acidergic transmission could represent an additional mechanism of action in Alzheimer's disease for some acetylcholinesterase inhibitors. (C) 2001 Elsevier Science B.V. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
